[Somatostatin receptors in non-endocrine tumours].

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Minerva Endocrinologica

• Publication date

  2001-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.DLD.2003.11.019PMID 11753238
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Octreotide

  2025cited by this paper
• Practical Program Evaluation: Assessing and Improving Planning, Implementation, and Effectiveness

  2005cited by this paper
• Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models.

  2002cited by this paper
• Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa.

  2002cited by this paper
• A randomized, multicenter prospective trial assessing long‐acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma

  2002cited by this paper
• Somatostatin Analogs in Oncology: A Look to the Future

  2001cited by this paper
• Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma

  2001cited by this paper
• Adjuvant chemotherapy for colon cancer

  2001cited by this paper
• Cancer survival increases in Europe, but international differences remain wide.

  2001cited by this paper
• Transcription of SST2 somatostatin receptor gene in human pancreatic cancer cells is altered by single nucleotide promoter polymorphism.

  2001cited by this paper
• Type-2 somatostatin receptor mRNA levels in breast and colon cancer determined by a quantitative RT-PCR assay based on dual label fluorogenic probe and the TaqMan technology.

  2001cited by this paper
• Cancer statistics, 2000

  2000cited by this paper
• Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238.

  2000cited by this paper
• Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome.

  2000cited by this paper
• Increased expression of the mRNA encoding the somatostatin receptor subtype five in human colorectal adenocarcinoma.

  2000cited by this paper
• A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma

  1999cited by this paper
• Gene Therapy for Pancreatic Carcinoma: Local and Distant Antitumor Effects after Somatostatin Receptor sst2 Gene Transfer

  1999cited by this paper
• No loss of sst receptors gene expression in advanced stages of colorectal cancer.

  1999cited by this paper
• Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies.

  1998cited by this paper
• Characterization of the promoter region of the human somatostatin receptor subtype 2 gene and localization of sequences required for estrogen-responsiveness.

  1998cited by this paper
• Mechanisms of Antineoplastic Action of Somatostatin Analogs

  1998cited by this paper
• Somatostatin in neuroblastoma and ganglioneuroma.

  1997cited by this paper
• Polymerase chain reaction compared with dot blotting for the determination of N‐myc gene amplification in neuroblastoma

  1997cited by this paper
• Somatostatin receptor subtypes sst1, sst2, sst3 and sst5expression in human pituitary, gastroentero‐pancreatic and mammary tumors

  1997cited by this paper
• Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors.

  1997cited by this paper
• Somatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae.

  1997cited by this paper
• N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.

  1997cited by this paper
• Analysis of somatostatin receptor subtype mRNA expression in human breast cancer.

  1997cited by this paper
• Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels.

  1996cited by this paper
• Estrogen regulates somatostatin receptor subtype 2 messenger ribonucleic acid expression in human breast cancer cells.

  1996cited by this paper
• Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer.

  1996cited by this paper
• Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma.

  1996cited by this paper
• Somatostatin and cancer.

  1996cited by this paper
• Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell lines and primary tumors using competitive reverse transcription-polymerase chain reaction.

  1996cited by this paper
• A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma

  1995cited by this paper
• A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy.

  1995cited by this paper
• Octreotide reduces the kinetic index, proliferating cell nuclear antigen–maximum proliferative index, in patients with colorectal cancer

  1995cited by this paper
• Dexamethasone regulates somatostatin receptor subtype messenger ribonucleic acid expression in rat pituitary GH4C1 cells.

  1995cited by this paper
• Inhibitory effect of the somatostatin analogue SMS 201-995 and cytokines on the proliferation of human colon adenocarcinoma cell lines.

  1995cited by this paper
• Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms.

  1995cited by this paper
• Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma.

  1995cited by this paper
• Point mutation of the somatostatin receptor 2 gene in the human small cell lung cancer cell line COR-L103.

  1995cited by this paper
• Prognostic prediction in neuroblastomas: clinical significance of combined analysis for Ha-ras p21 expression and N-myc gene amplification.

  1994cited by this paper
• Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization.

  1994cited by this paper
• Identification, characterization, and biological activity of somatostatin receptors in human neuroblastoma cell lines.

  1994cited by this paper
• Somatostatin-receptor scintigraphy in primary breast cancer.

  1994cited by this paper
• Octreotide has no effect on advanced colon cancer.

  1994cited by this paper
• Effects of new somatostatin analogs on the cell proliferation of colonic crypts and colonic cancers in rats.

  1993cited by this paper
• A cross-linking assay allows the detection of receptors for the somatostatin analogue, lanreotide in human breast tumours.

  1993cited by this paper
• Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype.

  1993cited by this paper
• Somatostatin inhibits both in-vitro and in-vivo carcinoembryonic antigen secretion by human colon cancer.

  1993cited by this paper
• Combined determination of n–myc oncogene amplification and dna ploidy in neuroblastoma complementary prognostic indicators

  1993cited by this paper
• 111In-octreotide scintigraphy in oncology.

  1993cited by this paper
• Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro.

  1992cited by this paper
• Somatostatin binding in normal and malignant human gastrointestinal mucosa.

  1992cited by this paper
• SMS 201.995 inhibits in vitro and in vivo growth of human colon cancer.

  1992cited by this paper
• Somatostatin receptors in human colorectal cancer.

  1992cited by this paper
• Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications.

  1992cited by this paper
• Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney.

  1992cited by this paper
• Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase.

  1992cited by this paper
• Treatment of liver metastases of human colon cancers in nude mice with somatostatin analogue RC‐160

  1992cited by this paper
• The Binding of Bombesin and Somatostatin and Their Analogs to Human Colon Cancers

  1992cited by this paper
• Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane.

  1991cited by this paper
• Inhibition of human breast cancer cell (MCF-7) growth in vitro by the somatostatin analog SMS 201-995: effects on cell cycle parameters and apoptotic cell death.

  1991cited by this paper
• P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma.

  1991cited by this paper
• Localization of progesterone receptors in pre- and postovulatory follicles of the domestic hen.

  1991cited by this paper
• Growth of human breast cancer cell lines is inhibited by the somatostatin analog BIM23014.

  1991cited by this paper
• Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.

  1990cited by this paper
• Somatostatin receptors in malignant tissues.

  1990cited by this paper
• Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: Relationship to egf receptors

  1990cited by this paper
• Principles and Practice of Pediatric Oncology

  1989cited by this paper
• Correlative study on neuro‐endocrine differentiation and presence of somatostatin receptors in breast carcinomas

  1989cited by this paper
• Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer.

  1989cited by this paper
• The relationship between somatostatin, epidermal growth factor, and steroid hormone receptors in breast cancer

  1989cited by this paper
• Synthesis of somatostatin by breast cancer cells and their inhibition by exogenous somatostatin and sandostatin.

  1989cited by this paper
• Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer.

  1989cited by this paper
• Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells.

  1987cited by this paper
• Analysis of N‐myc amplification in relation to disease stage and histologic types in human neuroblastomas

  1987cited by this paper
• Serum neuron‐specific enolase in children with neuroblastoma. Crelationship to stage and disease course

  1986cited by this paper
• Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

  1984cited by this paper
• Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma.

  1984cited by this paper
• A proposed staging for children with neuroblastoma. Children's cancer study group A

  1971cited by this paper
• [Malignant tumors of the breast].

  1960cited by this paper

• The role of [68Ga]Ga-DOTA-TATE PET/CT in breast cancer imaging: a prospective study compared with [18F]FDG PET/CT

  2025cites this paper
• Somatostatin and Its Receptor System in Colorectal Cancer

  2021cites this paper
• Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy

  2021cites this paper
• Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy

  2020cites this paper
• Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma

  2020cites this paper
• Two neuroendocrine G protein‐coupled receptor molecules, somatostatin and melatonin: Physiology of signal transduction and therapeutic perspectives

  2020cites this paper
• Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms

  2019cites this paper
• Neuropeptide G Protein-Coupled Receptors as Oncotargets

  2018cites this paper
• PET and PET/CT with 68Gallium-Labeled Somatostatin Analogues in Non GEP-NETs Tumors

  2014cites this paper
• Immunohistochemical expression of somatostatin receptor subtypes 2 and 5 in colorectal cancer

  2012cites this paper
• Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology

  2009cites this paper
• Diagnostic targeting of colon cancer using a novel fluorescent somatostatin conjugate in a mouse xenograft model

  2008cites this paper
• Immunohistochemical Detection and Localization of Somatostatin Receptor Subtypes in Prostate Tissue from Patients with Bladder Outlet Obstruction

  2008influential citation
• The GH1/IGF-1 axis polymorphisms and their impact on breast cancer development

  2007cites this paper
• lymphocytes in vitro by micronucleus assay

  2007cites this paper
• A radioiodinated MIBG-octreotate conjugate exhibiting enhanced uptake and retention in SSTR2-expressing tumor cells.

  2007cites this paper
• SLN Staging in Carcinoids and Neuroendocrine Tumors

  2005cites this paper
• Prognostic value of somatostatin receptor subtype 2 expression in colorectal cancer.

  2005cites this paper
• Molecular targets in pituitary tumours

  2004cites this paper